In episode 12 of the R&D Spotlight Series Avacta CEO Chris Coughlin and the team talk through updates to the pre|CISION linker design to enable duel payload release by a single FAP cleavage event. https://t.co/IhyxPGC4MT #AVCT

Avacta to Present First Dual Payload pre|CISION Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium. https://t.co/sQCSeStWJq #AVCT

In episode 11 of the R&D Spotlight series Avacta CEO Christina Coughlin discusses the latest updates to our intellectual property with the Chemistry team. https://t.co/e7Xt4Wz097 #AVCT

#AVCT announces the publication of the interim results for the six months ended June 30, 2025.

Notice of Interim Results and Investor Presentation. https://t.co/dmhF2Fd8eV #AVCT

Avacta’s pre|CISION Platform Shortlisted for the Technology of the Year Award at the AIM Awards. https://t.co/DMAoIEqKAz #AVCT

#AVCT updated website rolling out with the homepage. Gives a flavor for what our technology can do #HopeWithoutCompromise

New CB terms show @avacta confidence in securing funds to advance #preCISION assets thru clinical dev, supported by key #AVA6000 data in 25/26. 2nd equity raise to settle qtrly CB repayments w/ less dilution. For more on #AVCT

Avacta announces that all closing conditions to the sale of Coris Bioconcept SRL to 3B BlackBio Dx Ltd have been satisfied and the completion of the sale took place on Friday August 29, 2025. https://t.co/RBdh3ocM9y #AVCT

Amendments to the Convertible Bond and equity fundraise of £3.25 million. https://t.co/KjqLISJzn8 #AVCT

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress. https://t.co/OVgisjt8rv #AVCT

Avacta Announces Agreement to Sell Coris Bioconcept SRL. https://t.co/o0cC3wC0Oy #AVCT

In Episode 10 of the R&D Spotlight series we discuss endpoints in clinical trials, what the different kinds of responses mean and discuss the bystander effect. https://t.co/xUlWmnFqtr #AVCT

Avacta confirms that it has settled the quarterly principal of £2.55 million and interest repayment of c.£0.414 million in respect of the Company’s unsecured convertible bond in cash. https://t.co/vGHB21sK4j #AVCT

Avacta is pleased to announce that it has raised gross proceeds of £3.25 million from long term, high net worth investors introduced by Zeus Capital Limited. https://t.co/xwKPZSc1pB #AVCT

Avacta announces that at the Annual General Meeting held this morning, all resolutions were duly passed by shareholders (with the exception of Resolution 3 which was not put to the meeting). https://t.co/j6EYukcyAr #AVCT

Avacta Provides Q2 2025 Business Update Outlining Progress Against Strategic Objectives. https://t.co/pXYlcTWV7e #AVCT

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development. https://t.co/P2uiruUpGX #AVCT

Appointment of Zeus Capital as Joint Broker to Avacta Group plc. https://t.co/0LQdDuTxkL #AVCT

New IP & Tempus AI collaboration cld support @avacta's product & tech-based business dev. #preCISION pipeline progressing w #AVA6000 Ph I SGC data in H225 & TNBC in H126, & #AVA6103 IND enabling ongoing ahead of 2026 Ph I start. For more on #AVCT: